Hematology News

Sickle cell disease affects about 100,000 people in the United States, but the exact incidence is unknown and rates vary from state to state.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2022 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting.

An analysis of data registries from three countries showed the AstraZeneca vaccine was associated with small but increased rates of hospital contacts for thromboembolic coagulation disorders, especially for thrombocytopenia.

CHICAGO – Healio gathered the best, brightest and boldest group of oncologists during the ASCO Annual Meeting in Chicago to celebrate our inaugural Healio Disruptive Innovators.

The FDA granted fast track designation to VLX-1005 for treatment of heparin-induced thrombocytopenia.

The FDA granted breakthrough therapy designation to efanesoctocog alfa for treatment of hemophilia A.

ATLANTA — Researchers observed that PCI in patients with cancer is safe, regardless of cancer type or concomitant thrombocytopenia, and its use increased over time.

Apixaban dose reduction to 2.5 mg twice daily appeared safe after 6 months of full-dose treatment for venous thromboembolism among patients with cancer, according to a study published in Journal of Thrombosis and Haemostasis.

Individuals with long COVID may have a higher risk for abnormal blood clotting, especially those who have difficulties with basic exercise for more than 12 weeks after infection, according to a study published in Blood Advances.

THOROFARE, NJ — Healio is set to host the inaugural hematology/oncology Disruptive Innovators Award Reception during the American Society of Clinical Oncology Annual Meeting. The event will take place on June 4, 2022, at the Hyatt Regency McCormick Place in Chicago, Illinois.